…
HOYA Corporation, a med-tech company, provides high-tech and medical products in the Japan, Asia, the Americas, Europe, and internationally. The company operates through two segments: Life Care, and Information and Communications. It offers life care products, including eyeglasses; contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics, brain surgery, and dentistry. The company also operates Eyecity, a specialty retailer of contact lenses. In addition, it provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging related products that comprise optical glasses/optical lenses, colored glass filters, and UV light resources. Further, the company engages in research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. HOYA Corporation was founded in 1941 and is headquartered in Shinjuku, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
HOYA Corporation is a Japan-based manufacturer of optical products and precision glass, supplying eyeglass lenses, medical optics and photonics components for semiconductor and imaging markets. Long-term growth drivers include aging-driven demand for vision and ophthalmic devices, ongoing semiconductor and photonics investment, and product technology adoption; investors may find the company attractive for diversified exposure to healthcare and high-precision industrial optics and recurring demand characteristics.
Major risks include sensitivity to semiconductor-cycle downturns, regulatory and competitive pressures in medical devices and vision care, and currency and supply-chain exposure that could affect margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | 329730.49M | 259965.00M | 236564.00M | 215832.00M | 210706.00M |
| Minority interest | 1633.00M | 352.00M | -1190.00M | -150.00M | -815.00M |
| Net income | 254677.02M | 202102.00M | 181376.00M | 168638.00M | 164507.00M |
| Selling general administrative | 17973.00M | 20976.00M | 258379.00M | 16004.00M | 13186.00M |
| Selling and marketing expenses | - | 20976.00M | 18257.00M | 16004.00M | 13186.00M |
| Gross profit | 753355.29M | 766251.00M | 687990.00M | 631855.00M | 567283.00M |
| Reconciled depreciation | 58218.00M | 48577.00M | 47215.00M | 49615.00M | 43019.00M |
| Ebit | 281826.48M | 261424.00M | 238489.00M | 218730.00M | 213448.00M |
| Ebitda | 282193.14M | 310001.00M | 285704.00M | 268345.00M | 256467.00M |
| Depreciation and amortization | 366.66M | 48577.00M | 47215.00M | 49615.00M | 43019.00M |
| Operating income | 282193.14M | 480792.00M | 433453.00M | 218730.00M | 213448.00M |
| Other operating expenses | 671521.41M | 405023.00M | 359175.00M | 333231.00M | 306853.00M |
| Interest expense | 2003.53M | 1459.00M | 1925.00M | 1816.00M | 1664.00M |
| Tax provision | 76216.00M | 58215.00M | 53998.00M | 47044.00M | 45384.00M |
| Net interest income | -1991.00M | -1459.00M | -1925.00M | -1816.00M | -1664.00M |
| Income tax expense | 76695.74M | 58215.00M | 53998.00M | 47044.00M | 45384.00M |
| Total revenue | 953714.55M | 885815.00M | 792628.00M | 734095.00M | 670325.00M |
| Total operating expenses | 471162.15M | 285459.00M | 254537.00M | 230991.00M | 203811.00M |
| Cost of revenue | 200359.26M | 119564.00M | 104638.00M | 102240.00M | 103042.00M |
| Total other income expense net | 47537.35M | -220827.00M | -196889.00M | -2898.00M | -2742.00M |
| Net income from continuing ops | 251451.00M | 201750.00M | 182566.00M | 168788.00M | 165322.00M |
| Net income applicable to common shares | - | - | - | 168638.00M | 164507.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 1309085.42M | 1234278.00M | 1203623.00M | 1028326.00M | 992839.00M |
| Intangible assets | 21713.82M | 24637.00M | 34042.00M | 35732.00M | 35768.00M |
| Other current assets | 42434.43M | 39502.00M | 40554.00M | 30622.00M | 28197.00M |
| Total liab | 267565.64M | 262649.00M | 241359.00M | 213722.00M | 203783.00M |
| Total stockholder equity | 1026883.22M | 974023.00M | 967758.00M | 818321.00M | 803851.00M |
| Other current liab | 120942.58M | 73108.00M | 69139.00M | 82893.00M | 77559.00M |
| Common stock | 6303.43M | 6264.00M | 6264.00M | 6264.00M | 6264.00M |
| Capital stock | 6264.00M | 6264.00M | 6264.00M | 6264.00M | 6264.00M |
| Retained earnings | 908081.11M | 871357.00M | 805997.00M | 752999.00M | 802815.00M |
| Other liab | - | - | - | 41758.00M | 42640.00M |
| Good will | 54747.45M | 52174.00M | 52742.00M | 46818.00M | 39648.00M |
| Other assets | - | - | - | 9953.00M | 9096.00M |
| Cash | 574092.00M | 533967.00M | 525162.00M | 405888.00M | 419404.00M |
| Total current liabilities | 200930.84M | 179508.00M | 168908.00M | 156099.00M | 147380.00M |
| Current deferred revenue | - | - | 7353.00M | 23500.00M | 25247.00M |
| Net debt | -531851.00M | -496684.00M | -495923.00M | -381306.00M | -397804.00M |
| Short term debt | 10724.00M | 9276.00M | 8649.00M | 8585.00M | 7837.00M |
| Short long term debt | 10724.00M | 9276.00M | 8649.00M | 8585.00M | 7837.00M |
| Short long term debt total | 42241.00M | 37283.00M | 29239.00M | 24582.00M | 21600.00M |
| Other stockholder equity | -102561.53M | 96402.00M | -7984.00M | 59058.00M | -5228.00M |
| Property plant equipment | - | - | - | 178648.00M | 169665.00M |
| Total current assets | 966799.40M | 879731.00M | 856635.00M | 710155.00M | 682965.00M |
| Net tangible assets | - | - | - | 735771.00M | 728435.00M |
| Short term investments | 4751.00M | 4567.00M | 19237.00M | 20379.00M | 7223.00M |
| Net receivables | 213343.48M | 177145.00M | 152606.00M | 148116.00M | 136700.00M |
| Long term debt | 31517.00M | 28007.00M | 20590.00M | 15997.00M | 13763.00M |
| Inventory | 133315.90M | 124550.00M | 119076.00M | 105150.00M | 91441.00M |
| Accounts payable | 69264.25M | 68996.00M | 67771.00M | 64621.00M | 61984.00M |
| Accumulated other comprehensive income | 215060.22M | - | 163481.00M | - | - |
| Non currrent assets other | 652.08M | 53705.00M | 11629.00M | 21125.00M | 7910.00M |
| Non current assets total | 342286.02M | 354547.00M | 346988.00M | 318171.00M | 309874.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | 41406.00M | -33192.00M | -35808.00M | -47496.00M | 19.00M |
| Change to liabilities | - | - | - | -6507.00M | 5700.00M |
| Total cashflows from investing activities | -7633.75M | -33192.00M | -35808.00M | -47496.00M | -29298.00M |
| Net borrowings | 3148.00M | 9258.00M | -21.00M | -369.00M | -223.00M |
| Total cash from financing activities | -262903.48M | -190352.00M | -110892.00M | -194593.00M | -106722.00M |
| Change to operating activities | - | - | - | 4877.00M | -7837.00M |
| Net income | 254677.02M | 259965.00M | 236564.00M | 215832.00M | 210706.00M |
| Change in cash | 8980.82M | 8805.00M | 119274.00M | -13516.00M | 84507.00M |
| Begin period cash flow | 568724.77M | 525162.00M | 405888.00M | 419404.00M | 334897.00M |
| End period cash flow | 577705.59M | 533967.00M | 525162.00M | 405888.00M | 419404.00M |
| Total cash from operating activities | 280198.66M | 235113.00M | 222802.00M | 201829.00M | 190055.00M |
| Issuance of capital stock | 295.00M | 518.00M | 386.00M | 770.00M | 607.00M |
| Depreciation | 58584.45M | 48577.00M | 47215.00M | 49615.00M | 43019.00M |
| Other cashflows from investing activities | -76.33M | 9045.00M | 3664.00M | -2867.00M | -3834.00M |
| Dividends paid | 82418.53M | 38417.00M | 38778.00M | -39794.00M | -33201.00M |
| Change to inventory | 2037.75M | -9082.00M | -5283.00M | -9216.00M | -7092.00M |
| Change to account receivables | -18739.22M | -26521.00M | 800.00M | -2967.00M | -8696.00M |
| Sale purchase of stock | -173052.45M | -150012.00M | -56052.00M | -153973.00M | -65764.00M |
| Other cashflows from financing activities | -10897.16M | -11699.00M | -16427.00M | -1427.00M | -8341.00M |
| Change to netincome | - | - | - | -49805.00M | -45745.00M |
| Capital expenditures | 56937.15M | 47922.00M | 41074.00M | 33473.00M | 28872.00M |
| Change in working capital | -48186.41M | -33602.00M | -1305.00M | -18778.00M | -9386.00M |
| Other non cash items | 15123.60M | -39827.00M | -59672.00M | -44840.00M | -54284.00M |
| Free cash flow | 223261.52M | 187191.00M | 181728.00M | 168356.00M | 161183.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HOCPF HOYA Corporation |
-8.51 5.07% |
159.30 | 29.74 | 26.60 | 0.05 | 7.23 | 7.02 | 18.02 |
| ISRG Intuitive Surgical Inc |
3.88 0.89% |
440.75 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.00 0.95% |
208.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.89 1.80% |
103.04 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-0.66 0.33% |
197.94 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
HOYA Corporation, a med-tech company, provides high-tech and medical products in the Japan, Asia, the Americas, Europe, and internationally. The company operates through two segments: Life Care, and Information and Communications. It offers life care products, including eyeglasses; contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics, brain surgery, and dentistry. The company also operates Eyecity, a specialty retailer of contact lenses. In addition, it provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging related products that comprise optical glasses/optical lenses, colored glass filters, and UV light resources. Further, the company engages in research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. HOYA Corporation was founded in 1941 and is headquartered in Shinjuku, Japan.
Nittochi Nishishinjuku Building, Shinjuku, Japan, 160-8347
81 3 6911 4811
37752
| Name | Title | Year Born |
|---|---|---|
| Mr. Eiichiro Ikeda | Representative Exec. Officer, Pres, CEO & Chairperson of Board of Directors | 1970 |
| Mr. Ryo Hirooka | Representative Exec. Officer, CFO & Director | 1974 |
| Mr. Augustine G. Yee J.D. | Exec. Officer, Chief Bus. Devel. Officer & Chief Legal Officer | 1968 |
| Ms. Tomoko Nakagawa | Exec. Officer & Chief Sustainability (ESG) Officer | NA |
| Taishi Arashida | Officer of IR | NA |
| Mr. Eiichiro Ikeda | Representative Executive Officer, President, CEO & Chairperson of Board of Directors | 1970 |
| Mr. Ryo Hirooka | Representative Executive Officer, CFO & Director | 1974 |
| Ms. Tomoko Nakagawa | Executive Officer & Chief Sustainability (ESG) Officer | 1960 |
| Mr. Taishi Arashida | Officer of IR | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.